Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Frequently asked questions
What sector does Aurinia Pharmaceuticals Inc (IKAP) operate in?
Aurinia Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Aurinia Pharmaceuticals Inc (IKAP) current stock price?
As of the latest data, Aurinia Pharmaceuticals Inc stock price is €15.03, with a previous close of €14.82. Aurinia Pharmaceuticals Inc gained €0.22 in the last trading session, representing a 1.45% increase.
What is Aurinia Pharmaceuticals Inc (IKAP) current market capitalization?
Aurinia Pharmaceuticals Inc market cap is approximately 2.00 billion.
What is Aurinia Pharmaceuticals Inc (IKAP) Earnings Per Share (EPS)?
The trailing EPS is €1.95.
What is Aurinia Pharmaceuticals Inc (IKAP) Price-to-Earnings (P/E) ratio?
Aurinia Pharmaceuticals Inc current P/E ratio is 7.71.
What is Aurinia Pharmaceuticals Inc (IKAP) EBITDA?
Aurinia Pharmaceuticals Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 47.77 million.
Does Aurinia Pharmaceuticals Inc (IKAP) pay dividends?
No. Aurinia Pharmaceuticals Inc does not pay a dividend.
When is Aurinia Pharmaceuticals Inc (IKAP) next earnings report?
Aurinia Pharmaceuticals Inc is expected to release its next earnings report on September 30, 2026.
What is Aurinia Pharmaceuticals Inc (IKAP) beta (volatility) score?
Aurinia Pharmaceuticals Inc has a beta of 1.611, suggesting it is more volatile than the market.
